Abstract
Mucus hypersecretion is common in inflammatory and allergic lung disease. Excessive mucus production leads to obstruction of airways and favours bacterial colonization. Advances in understanding the signalling and transduction pathways of mucin gene expression as well as mechanisms of mucin protein production and secretion have defined new therapeutic targets. Conventional therapies include anticholinergics, β2-adrenoceptor agonists, glucocorticosteroids, mucolytics and macrolide antibiotics. Novel therapeutic approaches are inhibitors of cholinergic nerve activity, tachykinin receptor antagonists, epoxygenase inducers, inhibitors of mucin exocytosis, inhibitors of mucin synthesis and goblet cell hyperplasia, inducers of goblet cell apoptosis and P2Y2 purinoceptor antagonists to inhibit mucin secretion. After providing a short overview on conventional therapies this review will focus on new therapeutic targets.
Keywords: Airway, allergy, inflammation, mucus, treatment
Inflammation & Allergy - Drug Targets (Discontinued)
Title: Emerging Mucus Regulating Drugs in Inflammatory and Allergic Lung Disease
Volume: 7 Issue: 1
Author(s): Hans-Peter Hauber and Peter Zabel
Affiliation:
Keywords: Airway, allergy, inflammation, mucus, treatment
Abstract: Mucus hypersecretion is common in inflammatory and allergic lung disease. Excessive mucus production leads to obstruction of airways and favours bacterial colonization. Advances in understanding the signalling and transduction pathways of mucin gene expression as well as mechanisms of mucin protein production and secretion have defined new therapeutic targets. Conventional therapies include anticholinergics, β2-adrenoceptor agonists, glucocorticosteroids, mucolytics and macrolide antibiotics. Novel therapeutic approaches are inhibitors of cholinergic nerve activity, tachykinin receptor antagonists, epoxygenase inducers, inhibitors of mucin exocytosis, inhibitors of mucin synthesis and goblet cell hyperplasia, inducers of goblet cell apoptosis and P2Y2 purinoceptor antagonists to inhibit mucin secretion. After providing a short overview on conventional therapies this review will focus on new therapeutic targets.
Export Options
About this article
Cite this article as:
Hauber Hans-Peter and Zabel Peter, Emerging Mucus Regulating Drugs in Inflammatory and Allergic Lung Disease, Inflammation & Allergy - Drug Targets (Discontinued) 2008; 7 (1) . https://dx.doi.org/10.2174/187152808784165153
DOI https://dx.doi.org/10.2174/187152808784165153 |
Print ISSN 1871-5281 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4055 |
Related Articles
-
Cellular Mechanisms of Bypass Vein Graft Arterialization and Approaches to Attenuate Graft Remodeling
Vascular Disease Prevention (Discontinued) Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Paradoxical Thrombotic Effects of Aspirin: Experimental Study on 1000 Animals
Cardiovascular & Hematological Disorders-Drug Targets Anti-Inflammatory Drugs and Statins for Arterial Stiffness Reduction
Current Pharmaceutical Design Vascular microRNAs
Current Drug Targets Management of COVID-19 - A Review
Anti-Infective Agents Osmoadaptation of Mammalian Cells - An Orchestrated Network of Protective Genes
Current Genomics Crystallization and Preliminary X-Ray Crystallographic Studies on SICLP, a Novel Human Glyco_18 Domain – Containing Protein
Protein & Peptide Letters Oncogenic Role of SET/I2PP2A for Gynecologic Cancers
Current Drug Targets Aptamers: Molecular Tools for Medical Diagnosis
Current Topics in Medicinal Chemistry The Role of αA-Crystallin in Experimental Autoimmune Uveitis
Current Molecular Medicine Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects
Current Pharmaceutical Design Recents Patents for Isolating, Delivering and Tracking Adult Stem Cells in Regenerative Medicine
Recent Patents on Drug Delivery & Formulation Multiple Metamorphoses of CD38 from Prognostic Marker to Disease Modifier to Therapeutic Target in Chronic Lymphocytic Leukemia
Current Topics in Medicinal Chemistry Morphine as a Potential Oxidative Stress-Causing Agent
Mini-Reviews in Organic Chemistry Silver and Other Metals in the Treatment of Gastrointestinal Diseases
Current Medicinal Chemistry Safety and Efficacy of Duloxetine in the Treatment of Diabetic Peripheral Neuropathic Pain in Older Patients
Current Drug Safety Licensed DNA Vaccines against Infectious Hematopoietic Necrosis Virus (IHNV)
Recent Patents on DNA & Gene Sequences Aflibercept: A Novel VEGF Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Tumors
Mini-Reviews in Medicinal Chemistry Peripheral Neuropathy Induced by Paclitaxel: Recent Insights and Future Perspectives
Current Neuropharmacology